Cancer Research Technology

The new firm, created by Syncona and Cancer Research Technology, has raised $17.5 million to support development of individualized therapies targeted to tumor neoantigens.

Biomérieux has been awarded US Patent No. 8,106,172, "Nucleic acid sequences that can be used as primers and probes in the amplification and detection of SARS coronavirus."

In its companion diagnostics development program for an investigational PARP inhibitor oncologic, Pfizer is pursuing methylation-specific biomarkers rather than BRCA gene mutations to help personalize the drug.

MDxHealth will use its DNA methylation platform to identify and develop biomarkers that can predict patient response to a PARP inhibitor under development by Newcastle University, Cancer Research Technology, and Pfizer.

AstraZeneca and Cancer Research UK will contribute a combined £5.6 million ($8.9 million) to the Institute of Cancer Research to discover and develop cancer drugs that target molecular chaperones. AstraZeneca will have an exclusive worldwide license to compounds developed during the collaboration.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.